Oxford Immunotec announced a new local production initiative to bring the benefits of the T-SPOT.TB test to the Russian Federation. Since the T-SPOT.TB test received approval in the Russian Federation in 2013, Oxford Immunotec has been working with a local distribution partner, PharmLine and has seen expanding uptake of the T-SPOT.TB test. In collaboration with PharmLine, Oxford Immunotec will now also be working with Generium, who will be manufacturing the T-SPOT.TB test locally at their factory in the Vladimir region of the Russian Federation. This is expected to reduce the cost of, and expand access to, the T-SPOT.TB test for patients in the Russian Federation. Additionally, Generium will be working with PharmLine on marketing and distribution of the T-SPOT.TB test, including applying for national TB control tenders.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.